Clinical administration rosiglitazone and glimepiride combination in the treatment of type 2 diabetes mellitus;Roziglitazon és glimepirid kombinációs készítmény klinikai alkalmazása 2-es típusú diabetes mellitus kezelésében

Orvosi Hetilap

Volumn 148, Issue 49, 2007, Pages 2331-2335

  Fehér, János ^a,b   Lengyel, Gabriella ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NONE   (Hungary)

Author keywords

Avaglim; Glimepiride; Non insulin dependent diabetes mellitus; Rosiglitazone

Indexed keywords

GLIMEPIRIDE; GLIMEPIRIDE PLUS ROSIGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ARTICLE; CELL STIMULATION; DRUG MECHANISM; DRUG TOLERABILITY; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL;

EID: 37349008314     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2007.28259     Document Type: Article

References (30)

1. Fehér J., Lengyel G.: Tápláozás és a szív-és érrendszeri beteg-ségek miatti halálozás. Orv. Hetil., 2006, 147, 1491-1496.
2. Derosa, G., Cicero, A. F G., D'Angelo, A. és mtsai: Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens. Res., 2005, 28, 917-924.
3. Fukuen, S., Iwaki, M., Yasui, A. és mtsai: Sulfonylurea agents exhibit peroxisome proliferator-activated receptor agonistic activity. J. Biol. Chem., 2005, 280, 23653-23659.
4. Pfützner, A., Wilhelm, B., Forst, T.: Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination. Vasc. Health Risk Manag., 2007, 3, 211-220.
5. Sheehan, M. T.: Current Therapeutic Options in Type 2 Diabetes Mellitus: A Practical Approach. Clinical Medicine & Research, 2003, 1, 189-200.
6. Zimmerman, B. R.: Sulfonylureas. Endocrinol Metab. Clin. North Am., 1997, 26, 511-522.
7. Fukuen, S., Iwaki, M., Yasui, A. és mtsai: Sulfonylurea Agents Exhibit Peroxisome Proliferator-activated Receptor γ Agonistic Activity. J. Biol. Chem., 2005, 280, 23653-23659.
8. Damsbo, P., Clauson, P., Marbury, T. C. és mtsa: A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care, 1999, 22, 789-794.
9. DeFronzo, R. A., Goodman, A. M.: The Multicenter Metformin Study Group. Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus. N. Engl. J. Med., 1995, 333, 541-549.
10. Hundal, R. S, Krssak, M., Dufour, S. és mtsai: Mechanism by which metformin reduces glucose production in type 2 diabetes. D iabetes, 2000, 49, 2063-2069.
11. Abbasi, F., Carantoni, M., Chen, Y. D. és mtsai: Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin. Diabetes Care, 1998, 21, 1301-1305.
12. Palumbo, P J.: Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J. Diabetes Complications, 1998, 12, 110-119.
13. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352, 854-865.
14. Garber, A. J., Duncan, T G., Goodman, A. M. És mtsai: Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am. J. Med., 1997, 103, 491-497.
15. Lebovitz, H. E., Kreider, M., Freed, M. I.: Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care, 2002, 25, 815-821.
16. Ovalle, F., Bell, D. S. H.: Effect of Rosiglitazone Versus Insulin on the Pancreatic Cell Function of Subjects With Type 2 Diabetes. Diabetes Care, 2004, 27, 2585-2589.
17. Viberti, G., Kahn, S. E., Greene, D. A. és mtsai: A diabetes outcome progression trial (ADOPT): an international multi-center study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care, 2002, 25, 1737-1743.
18. Freed, M. I., Ratner, R., Marcovina, S. M. és mtsai: Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am. J. Cardiol., 2002, 90, 947-952.
19. Parulkar, A. A., Pendergrass, M. L., Granda-Ayala, R. és mtsai: Nonhypoglycemic effects of thiazolidinediones. Ann. Intern. Med., 2001, 134, 61-71.
20. Raji, A., Plutzky, J.: Insulin resistance, diabetes and atherosclerosis: thiazolidinediones as therapeutic interventions. Curr. Cardiol. Rep., 2002, 4, 514-521.
21. Mittermayer, F., Schaller, G., Pleiner, J. és mtsai: Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction. M. J. Clin. Endocrinol. Metab., 2007. May 1.; [Epub ahead of print]
22. Kerenyi, Zs., Samer, H., James, R. és mtsai: Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2004, 63, 213-223.
23. Home, P. D., Pocock, S. J. Beck-Nielsen, H. és mtsai: Rosiglitazone Evaluated for Cardiovascular Outcomes - An Interim Analysis. NEJM, 2007, 357, 28-38.
24. Kim, H. J, Kang, E. S., Kim, D. J. és mtsai: Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clinical Endocrinology, 2007, 66, 282-289.
25. Psaty, B. M., Furberg, C. D.: The record on rosiglitazone and the risk of myocardial infarction. N. Engl. J. Med., 2007, 357, 67-69.; Epub. 2007. Jun. 5.
26. de Dios, S. T., Frontanilla, K. V., Nigro, J. és mtsai: Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents. J. Diabetes Complicat., 2007, 21, 108-117.
27. de Dios, S. T., Bruemmer, D., Dilley, R. J. és mtsai: Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery and saphenous; vein smooth muscle cell proliferation. Circulation, 2003, 107, 2548-2550.
28. Haberbosch, W.: Einfluss der Thiazolidindione auf die diabetestypische Dyslipidämie: Wirken alle gleichermaßen gefäßprotektiv? Herz, 2007, 32, 51-57.
29. Jermendy Gy.: Új fix kombináció a 2-es típusú diabetesz kezelésében. Medical Tribune, 2007, 18.
30. Pfützner, A., Schöndorf, T., Seidel, D. és mtsai: Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Metabol. Clin. Exp., 2006, 55, 20-25.